Original from: Labpulse.com
Eli Lilly has opened a new R&D facility in the Boston Seaport district with the aim of advancing the firm's RNA and DNA-based therapies, as well as discovering new drug targets and developing new medicines.
The new 346,000-sq-ft Lilly Seaport Innovation Center (LSC) facility, occupying a 12-story building, will serve to accommodate approximately 500 Lilly scientists and researchers, as well as an additional 200 people from other companies through Lilly Gateway Labs, Lilly's hosting program for biotech firms.
According to a statement from Lilly, the firm has plans to expand the Gateway Labs program in 2024 to four sites, including San Francisco, San Diego, and the new site in Boston.
"The opening of LSC expands upon Lilly's long-standing presence in the Boston area," Dr. Daniel Skovronsky, PhD, chief scientific officer and president of Lilly Research Laboratories and president of Lilly Immunology, said in the firm's statement.
"We are committed to being supportive neighbors in this hub of discovery and innovation, further collaborating with leading institutions and new talent to continue delivering transformative medicines for the people who need them most."
